- CA$6.16m
- CA$7.26m
- CA$0.43m
Brief: Kane Biotech Announces Q2 Earnings Per Share $0.021
Brief: Kane Biotech Awarded $3.8 Mln In Non-Dilutive Government Funding
Brief: Kane Biotech Announces New Agreement With FreeMind Group
Brief: Kane Biotech And Nestlé Reach Settlement
Brief: Kane Biotech Inc Reports Q1 Loss Per Share Of $0.008
Brief: Kane Biotech Provides Update On Exclusive License And Distribution Agreement With Dechra Veterinary Products
Brief: Kane Biotech Qtrly Loss Per Share $0.008
Brief: Kane Biotech Signs Distribution Agreement And Secures First Order From China
Brief: Eastern Missouri Court Rules In Favor Of Kane Biotech In Lawsuit Against Nestle Purina
Brief: Kane Biotech Will Be Launching 4 New Products Under Bluestem Brand In Canada & U.S. In Q1 Of 2019
Brief: Kane Biotech Inc - QTRLY Loss Per Share (Post Consolidation) $0.012
Brief: Kane Biotech Announces Departure Of CEO
Brief: Kane Biotech Reports Qtrly Loss Per Share (Post Consolidation) Of $0.009
Brief: Kane Biotech Extends Research Agreement With USAISR
Brief: Kane Biotech Granted Wound Care Patent
Brief: Kane Biotech Reports Qtrly Loss Per Share (Post Consolidation) $0.011
Brief: Kane Biotech appoints Ray Dupuis as chief financial officer
Brief: Kane Biotech announces removal of all debt from its balance sheet and grant of options
Brief: Philip Renaud says Renaud, entity over which he exercises control now own about 30.56 pct of shares of Kane Biotech